Search research articles
Contact Us
Filters
Showing results (21-30 of 83) with videos related to
Page
of 9
Sort By:
Journal of Managed Care & Specialty Pharmacy
|
January 2, 2018
The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis
Jason Shafrin, Mahlet Gizaw Tebeka, Kwanza Price, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 2, 2024
Will the Institute for Clinical and Economic Review's Shared Savings Approach Decrease Value-Based Prices Most for the Most Severe Diseases?
Jason Shafrin, Shanshan Wang, Khounish Sharma, et al.
Digital Health
|
March 17, 2022
Are caregivers ready for digital? Caregiver preferences for health technology tools to monitor medication adherence among patients with serious mental illness
Felicia Forma, Kevin Chiu, Jason Shafrin, et al.
Journal of Managed Care & Specialty Pharmacy
|
June 27, 2025
Cost-effectiveness analysis model for sotagliflozin compared with insulin monotherapy for patients with type 1 diabetes and chronic kidney disease
Jaehong Kim, Shanshan Wang, Moises Marin, et al.
The American Journal of Managed Care
|
August 16, 2017
The cost of adherence mismeasurement in serious mental illness: a claims-based analysis
Jason Shafrin, Felicia Forma, Ethan Scherer, et al.
Health Services Research
|
February 14, 2015
Regional Growth in Medicare Spending, 1992-2010
Camille Chicklis, Thomas MaCurdy, Jay Bhattacharya, et al.
Clinical Nutrition ESPEN
|
April 10, 2026
Quantifying the Lifetime Economic Impact of Pediatric Oral Nutritional Supplements
Kyi-Sin Than, Khounish Sharma, Kirk W Kerr, et al.
Pharmacoeconomics
|
February 10, 2019
A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis
Devin Incerti, Jeffrey R Curtis, Jason Shafrin, et al.
Journal of Medical Economics
|
January 10, 2026
Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria: implications for decision-making
Kyi-Sin Than, Jason Shafrin, Sanjana Muthukrishnan, et al.
Advances in Therapy
|
November 5, 2024
A Retrospective Claims Analysis of the Rate of Complications in Patients Undergoing Treatment for Paroxysmal Nocturnal Hemoglobinuria
Denise Clayton, Jason Shafrin, Glorian P Yen, et al.
Page
of 9
Search research articles
Search
Showing results (21-30 of 83) with videos related to
Sort By:
Page
of 9
Journal of Managed Care & Specialty Pharmacy
|
January 2, 2018
The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis
Jason Shafrin, Mahlet Gizaw Tebeka, Kwanza Price, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 2, 2024
Will the Institute for Clinical and Economic Review's Shared Savings Approach Decrease Value-Based Prices Most for the Most Severe Diseases?
Jason Shafrin, Shanshan Wang, Khounish Sharma, et al.
Digital Health
|
March 17, 2022
Are caregivers ready for digital? Caregiver preferences for health technology tools to monitor medication adherence among patients with serious mental illness
Felicia Forma, Kevin Chiu, Jason Shafrin, et al.
Journal of Managed Care & Specialty Pharmacy
|
June 27, 2025
Cost-effectiveness analysis model for sotagliflozin compared with insulin monotherapy for patients with type 1 diabetes and chronic kidney disease
Jaehong Kim, Shanshan Wang, Moises Marin, et al.
The American Journal of Managed Care
|
August 16, 2017
The cost of adherence mismeasurement in serious mental illness: a claims-based analysis
Jason Shafrin, Felicia Forma, Ethan Scherer, et al.
Health Services Research
|
February 14, 2015
Regional Growth in Medicare Spending, 1992-2010
Camille Chicklis, Thomas MaCurdy, Jay Bhattacharya, et al.
Clinical Nutrition ESPEN
|
April 10, 2026
Quantifying the Lifetime Economic Impact of Pediatric Oral Nutritional Supplements
Kyi-Sin Than, Khounish Sharma, Kirk W Kerr, et al.
Pharmacoeconomics
|
February 10, 2019
A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis
Devin Incerti, Jeffrey R Curtis, Jason Shafrin, et al.
Journal of Medical Economics
|
January 10, 2026
Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria: implications for decision-making
Kyi-Sin Than, Jason Shafrin, Sanjana Muthukrishnan, et al.
Advances in Therapy
|
November 5, 2024
A Retrospective Claims Analysis of the Rate of Complications in Patients Undergoing Treatment for Paroxysmal Nocturnal Hemoglobinuria
Denise Clayton, Jason Shafrin, Glorian P Yen, et al.
Page
of 9